Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
Journal Article
BACKGROUND: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades. CASE PRESENTATION: Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C. CONCLUSIONS: While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.
Full Text
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
Duke Authors
Cited Authors
- Abel, ML; Kokosis, G; Blazer, DG
Published Date
- February 20, 2017
Published In
Volume / Issue
- 15 / 1
Start / End Page
- 49 -
PubMed ID
- 28219391
Pubmed Central ID
- 28219391
Electronic International Standard Serial Number (EISSN)
- 1477-7819
Digital Object Identifier (DOI)
- 10.1186/s12957-016-1047-6
Language
- eng
Conference Location
- England